Longitudinal trajectory and characterization of cancer-related cognitive impairment in a nationwide cohort study Journal Article


Authors: Janelsins, M. C.; Heckler, C. E.; Peppone, L. J.; Ahles, T. A.; Mohile, S. G.; Mustian, K. M.; Palesh, O.; O’Mara, A. M.; Minasian, L. M.; Williams, A. M.; Magnuson, A.; Geer, J.; Dakhil, S. R.; Hopkins, J. O.; Morrow, G. R.
Article Title: Longitudinal trajectory and characterization of cancer-related cognitive impairment in a nationwide cohort study
Abstract: Purpose Cancer-related cognitive impairment (CRCI) is an important clinical problem in patients with breast cancer receiving chemotherapy. Nationwide longitudinal studies are needed to understand the trajectory and severity of CRCI in specific cognitive domains. Patients and Methods The overall objective of this nationwide, prospective, observational study conducted within the National Cancer Institute Community Clinical Oncology Research Program was to assess trajectories in specific cognitive domains in patients with breast cancer (stage I-IIIC) receiving chemotherapy, from pre- (A1) to postchemotherapy (A2) and from prechemotherapy to 6 months postchemotherapy (A3); controls were assessed at the same time-equivalent points. The primary aim assessed visual memory using the Cambridge Neuropsychological Test Automated Battery Delayed Match to Sample test by longitudinal mixed models including A1, A2, and A3 and adjusting for age, education, race, cognitive reserve score, and baseline anxiety and depressive symptoms. We also assessed trajectories of CRCI in other aspects of memory as well as in attention and executive function with computerized, paper-based, and telephone-based cognitive tests. Results In total, 580 patients with breast cancer (mean age, 53.4 years) and 363 controls (mean age, 52.6 years) were assessed. On the Delayed Match to Sample test, the longitudinal mixed model results revealed a significant group-by-time effect (P < .005); patients declined over time from prechemotherapy (A1) to 6 months postchemotherapy (A3; P = .005), but controls did not change (P = .426). The group difference between patients and controls was also significant, revealing declines in patients but not controls (P = .017). Several other models of computerized, standard, and telephone tests indicated significantly worse performance by patients compared with controls from pre- to postchemotherapy and from prechemotherapy to 6 months postchemotherapy. Conclusion This nationwide study showed CRCI in patients with breast cancer affects multiple cognitive domains for at least 6 months postchemotherapy. Copyright © 2018 American Society of Clinical Oncology. All rights reserved.
Journal Title: Journal of Clinical Oncology
Volume: 36
Issue: 32
ISSN: 0732-183X
Publisher: American Society of Clinical Oncology  
Date Published: 2018-11-10
Start Page: 3231
End Page: 3239
Language: English
DOI: 10.1200/jco.2018.78.6624
PROVIDER: scopus
PMCID: PMC6225503
PUBMED: 30240328
DOI/URL:
Notes: Article -- Export Date: 3 December 2018 -- Source: Scopus
Altmetric Score
MSK Authors
  1. Tim A Ahles
    94 Ahles